GlassScriptPhysician profile
Marc S Richards
NPI 1760643282
$61,398.57
in general payments reported to CMS, 2019-2025
27 companies · $31K in 2025
The $31K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $97.02 · 2021: $636 · 2022: $891 · 2023: $6,254 · 2024: $22K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Honoraria: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $6,958 · Travel and Lodging: $1,752 · Education: $89.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,164.00 |
| Honoraria | $13,062.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,821.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,805.00 |
| Food and Beverage | $6,957.78 |
| Travel and Lodging | $1,752.27 |
| Education | $89.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $17,654.67 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $15,099.86 | 2022-2025 | Tarpeyo |
| Apellis Pharmaceuticals, INC. | $9,570.30 | 2025 | Empaveli |
| Amgen INC. | $7,353.08 | 2021-2025 | Tavneos, Parsabiv, Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,957.66 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $3,299.35 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,240.24 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $532.22 | 2021-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $402.56 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $361.36 | 2020-2024 | Acthar, Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.75 | 2022-2025 | Jardiance |
| Horizon Therapeutics Plc | $265.96 | 2021-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $264.95 | 2021-2025 | Rayaldee |
| Vifor Pharma, INC. | $257.92 | 2020-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $147.14 | 2020-2023 | Benlysta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $128.26 | 2021-2025 | Lupkynis |
| Novo Nordisk INC | $105.28 | 2024-2025 | Ozempic, Wegovy |
| Fresenius USA Marketing, INC. | $92.13 | 2021-2025 | Velphoro, Velphoro |
| Cormedix INC. | $78.49 | 2024-2025 | Defencath, Defencath |
| Ardelyx, INC. | $73.91 | 2024-2025 | Ibsrela |
| Genentech USA, INC. | $31.27 | 2025 | Gazyva |
| Lilly USA, LLC | $30.62 | 2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $28.61 | 2022 | |
| Ani Pharmaceuticals, INC. | $27.19 | 2025 | Purified Cortrophin Gel |
| Medtronic, INC. | $27.16 | 2023 | Ellipsys Vascular Access System |
| Alexion Pharmaceuticals, INC. | $23.67 | 2022 | |
| Akebia Therapeutics INC | $13.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.